高级检索
当前位置: 首页 > 详情页

Impact of Cellular Immune Function on Prognosis of Lung Cancer Patients after Cytokine-induced Killer Cell Therapy

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University), [2]Epidemiology and Biostatistics Department, School of Public Health, Kunming Medical University, [3]Breast Disease Center, The First Peoples´ Hospital of Kunming, Yunnan Province, Kunming, China, [4]Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
出处:
ISSN:

关键词: CIK cell lung cancer prognosis immune function

摘要:
Aims: To investigate changes in cellular immune function of patients with lung cancer before and after cytokine-induced killer (CIK) cell therapy and to identify variation effects on overall survival (OS) and progression-free survival (PFS). Materials and Methods: A total of 943 lung cancer patients with immune dysfunction were recruited from January 2002 to January 2010, 532 being allocated to conventional therapy and 411 to CIK therapy after a standard treatment according to the NCCN Clinical Practice Guidelines. All the patients were investigated for cellular immune function before and after therapy every three months. and clinical prognostic outcomes were analyzed. Results: After six courses of treatment, immune function was much improved in patients receiving CIK cells therapy as compared to controls. The percentages of recurrence and/or metastases for patients undergoing CIK cell therapy was 56.2% and 49.1% respectively but 78.6% and 70.3% among controls (p<0.001). The median OS times for CIK cell therapy and control groups were 48 and 36 months respectively. The OS rates at 12, 36, 60, 84 months in CIK treated patients were 97.8%, 66.9%, 27.7%, and 4.1% while they were 92.3%, 44.5%, 9.2%, and 1.5% in controls. OS and PFS were significantly different by log rank test between the two groups and across the three immune improvement classes. Conclusions: The immune function of lung cancer patients was improved by CIK cell therapy, associated with an increase in the OS rate and extension of the time to recurrence and/or metastasis.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
JCR分区:
出版当年[2013]版:
Q4 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University),
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82490 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号